Randomized phase II trial of MRI-guided salvage radiotherapy for prostate cancer in 4 weeks versus 2 weeks (SHORTER).
Genitourinary
Hypofractionation
MR-Linac
MRI-guided radiotherapy (MRgRT)
Prostate cancer
Salvage radiotherapy
Stereotactic body radiotherapy (SBRT)
Toxicity
Ultra-hypofractionated
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
22 Aug 2023
22 Aug 2023
Historique:
received:
22
03
2023
accepted:
08
08
2023
medline:
24
8
2023
pubmed:
23
8
2023
entrez:
23
8
2023
Statut:
epublish
Résumé
Ultra-hypofractionated image-guided stereotactic body radiotherapy (SBRT) is increasingly used for definitive treatment of localized prostate cancer. Magnetic resonance imaging-guided radiotherapy (MRgRT) facilitates improved visualization, real-time tracking of targets and/or organs-at-risk (OAR), and capacity for adaptive planning which may translate to improved targeting and reduced toxicity to surrounding tissues. Given promising results from NRG-GU003 comparing conventional and moderate hypofractionation in the post-operative setting, there is growing interest in exploring ultra-hypofractionated post-operative regimens. It remains unclear whether this can be done safely and whether MRgRT may help mitigate potential toxicity. SHORTER (NCT04422132) is a phase II randomized trial prospectively evaluating whether salvage MRgRT delivered in 5 fractions versus 20 fractions is non-inferior with respect to gastrointestinal (GI) and genitourinary (GU) toxicities at 2-years post-treatment. A total of 136 patients will be randomized in a 1:1 ratio to salvage MRgRT in 5 fractions or 20 fractions using permuted block randomization. Patients will be stratified according to baseline Expanded Prostate Cancer Index Composite (EPIC) bowel and urinary domain scores as well as nodal treatment and androgen deprivation therapy (ADT). Patients undergoing 5 fractions will receive a total of 32.5 Gy over 2 weeks and patients undergoing 20 fractions will receive a total of 55 Gy over 4 weeks, with or without nodal coverage (25.5 Gy over 2 weeks and 42 Gy over 4 weeks) and ADT as per the investigator's discretion. The co-primary endpoints are change scores in the bowel and the urinary domains of the EPIC. The change scores will reflect the 2-year score minus the pre-treatment (baseline) score. The secondary endpoints include safety endpoints, including change in GI and GU symptoms at 3, 6, 12 and 60 months from completion of treatment, and efficacy endpoints, including time to progression, prostate cancer specific survival and overall survival. The SHORTER trial is the first randomized phase II trial comparing toxicity of ultra-hypofractionated and hypofractionated MRgRT in the salvage setting. The primary hypothesis is that salvage MRgRT delivered in 5 fractions will not significantly increase GI and GU toxicities when compared to salvage MRgRT delivered in 20 fractions. ClinicalTrials.gov Identifier: NCT04422132. Date of registration: June 9, 2020.
Sections du résumé
BACKGROUND
BACKGROUND
Ultra-hypofractionated image-guided stereotactic body radiotherapy (SBRT) is increasingly used for definitive treatment of localized prostate cancer. Magnetic resonance imaging-guided radiotherapy (MRgRT) facilitates improved visualization, real-time tracking of targets and/or organs-at-risk (OAR), and capacity for adaptive planning which may translate to improved targeting and reduced toxicity to surrounding tissues. Given promising results from NRG-GU003 comparing conventional and moderate hypofractionation in the post-operative setting, there is growing interest in exploring ultra-hypofractionated post-operative regimens. It remains unclear whether this can be done safely and whether MRgRT may help mitigate potential toxicity. SHORTER (NCT04422132) is a phase II randomized trial prospectively evaluating whether salvage MRgRT delivered in 5 fractions versus 20 fractions is non-inferior with respect to gastrointestinal (GI) and genitourinary (GU) toxicities at 2-years post-treatment.
METHODS
METHODS
A total of 136 patients will be randomized in a 1:1 ratio to salvage MRgRT in 5 fractions or 20 fractions using permuted block randomization. Patients will be stratified according to baseline Expanded Prostate Cancer Index Composite (EPIC) bowel and urinary domain scores as well as nodal treatment and androgen deprivation therapy (ADT). Patients undergoing 5 fractions will receive a total of 32.5 Gy over 2 weeks and patients undergoing 20 fractions will receive a total of 55 Gy over 4 weeks, with or without nodal coverage (25.5 Gy over 2 weeks and 42 Gy over 4 weeks) and ADT as per the investigator's discretion. The co-primary endpoints are change scores in the bowel and the urinary domains of the EPIC. The change scores will reflect the 2-year score minus the pre-treatment (baseline) score. The secondary endpoints include safety endpoints, including change in GI and GU symptoms at 3, 6, 12 and 60 months from completion of treatment, and efficacy endpoints, including time to progression, prostate cancer specific survival and overall survival.
DISCUSSION
CONCLUSIONS
The SHORTER trial is the first randomized phase II trial comparing toxicity of ultra-hypofractionated and hypofractionated MRgRT in the salvage setting. The primary hypothesis is that salvage MRgRT delivered in 5 fractions will not significantly increase GI and GU toxicities when compared to salvage MRgRT delivered in 20 fractions.
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov Identifier: NCT04422132. Date of registration: June 9, 2020.
Identifiants
pubmed: 37608258
doi: 10.1186/s12885-023-11278-3
pii: 10.1186/s12885-023-11278-3
pmc: PMC10463903
doi:
Substances chimiques
Androgen Antagonists
0
Banques de données
ClinicalTrials.gov
['NCT04422132']
Types de publication
Clinical Trial, Phase II
Randomized Controlled Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
781Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Int J Radiat Oncol Biol Phys. 2020 Jun 1;107(2):297-298
pubmed: 32386737
Lancet. 2019 Aug 3;394(10196):385-395
pubmed: 31227373
Int J Radiat Oncol Biol Phys. 2010 Feb 1;76(2):361-8
pubmed: 19394158
Can J Urol. 2008 Feb;15(1):3866-71
pubmed: 18304396
J Clin Oncol. 2009 Jun 20;27(18):2924-30
pubmed: 19433689
JAMA Netw Open. 2020 Feb 5;3(2):e1920471
pubmed: 32022878
JAMA Netw Open. 2020 Aug 3;3(8):e2014674
pubmed: 32865572
Int J Radiat Oncol Biol Phys. 2018 Mar 15;100(4):858-865
pubmed: 29485063
Lancet. 2020 Oct 31;396(10260):1422-1431
pubmed: 33002431
JAMA Oncol. 2023 Mar 1;9(3):365-373
pubmed: 36633877
JAMA Oncol. 2021 Apr 1;7(4):544-552
pubmed: 33570548
Quant Imaging Med Surg. 2022 Feb;12(2):1585-1607
pubmed: 35111651
Lancet. 2020 Oct 31;396(10260):1413-1421
pubmed: 33002429
Int J Radiat Oncol Biol Phys. 2023 Feb 1;115(2):327-336
pubmed: 35985457
J Clin Oncol. 2016 Jul 10;34(20):2325-32
pubmed: 27044935
Eur Urol Open Sci. 2020 Oct 23;22:9-16
pubmed: 34337473
Lancet. 2012 Dec 8;380(9858):2018-27
pubmed: 23084481
JAMA. 2006 Nov 15;296(19):2329-35
pubmed: 17105795
Int J Radiat Oncol Biol Phys. 2021 Jun 1;110(2):596-608
pubmed: 33412260
Lancet. 2022 May 14;399(10338):1886-1901
pubmed: 35569466
N Engl J Med. 2016 Oct 13;375(15):1425-1437
pubmed: 27626365
Int J Radiat Oncol Biol Phys. 2023 Jan 1;115(1):142-152
pubmed: 36007724
JAMA. 1999 May 5;281(17):1591-7
pubmed: 10235151
Ann Oncol. 2022 Sep;33(9):950-958
pubmed: 35636621
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
Lancet Oncol. 2020 Oct;21(10):1331-1340
pubmed: 33002437
BJU Int. 2011 Feb;107(4):576-84
pubmed: 20735387
Lancet Oncol. 2020 Oct;21(10):1341-1352
pubmed: 33002438